Cempra Inc's experimental drug to treat community-acquired pneumonia, the kind recently suffered by presidential candidate Hillary Clinton, causes a potentially concerning rise in liver enzymes, according to a preliminary review by the U.S. Food and Drug Administration.
Cempra's shares fell as much as 41 percent on the news.
The review, posted on the FDA's website on Wednesday, comes two days ahead of a meeting of outside experts who will discuss the drug, solithromycin, and recommend whether or not it should be approved.
Cempra's shares fell as much as 41 percent on the news.
The review, posted on the FDA's website on Wednesday, comes two days ahead of a meeting of outside experts who will discuss the drug, solithromycin, and recommend whether or not it should be approved.
